Clinical Trial Update: A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults and Adults With FV Leiden or Prothrombin G20210A Mutation [Phase 1]

View source ↗

Summary

City Therapeutics' CITY-FXI is being studied in a Phase 1 single ascending dose trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics in h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Factor Leiden Thrombophilia
• Prothrombin G20210a-related Thrombophilia

Drugs mentioned

• CITY-FXI

Snippet

Sponsor: City Therapeutics | Conditions: Factor V Leiden, Prothrombin G20210A | Phase 1 | Status: RECRUITING